Ikena Oncology, Inc.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Ikena Oncology Inc is a targeted oncology company developing precision medicines tailored to biomarker-defined patient groups with specific unmet needs. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway. The Hippo pathway is genetically altered in approximately 10% of human cancers and is widely accepted as a prevalent driver of cancer pathogenesis and a mediator of poor outcomes for patients. its other product candidates are IK-175 and IK-595.

NASDAQ:IKNA

Ikena Oncology, Inc.

$

Last Close

6.45

01/06 14:25

Market Cap

233.9M

Beta: -

Volume Today

5.888K

Avg: 108.9K

PE Ratio

5.29

PEG: 0.08

industry

exchange

website

ipo date

full time employees

currency

Earnings

Earnings per Share (Estimate)

Revenue (Estimate)

Related Tickers

DUETU

IIIIU

ZTAQU

JWAC

GDNRU

VPCBU

FINMW

VERY

HNNAZ

Metrics